



? Full Text

Share

Review

May 19, 2020

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review

April W. Armstrong, MD, MPH¹; Charlotte Read, MBBS, BSc^{1,2}

? Author Affiliations

JAMA. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006

Abstract

Importance Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders.

Observations Plaque psoriasis is the most common variant of psoriasis. The most rapid advancements addressing plaque psoriasis have been in its pathogenesis, genetics, comorbidities, and biologic treatments. Plaque psoriasis is associated with a number of comorbidities including psoriatic arthritis, cardiometabolic diseases, and depression. For patients with mild psoriasis, topical agents remain the mainstay of treatment, and they include topical corticosteroids, vitamin D analogues, calcineurin inhibitors, and keratolytics. The American Academy of Dermatology-National Psoriasis Foundation guidelines recommend biologics as an option for first-line treatment of moderate to severe plaque psoriasis because of their efficacy in treating it and acceptable safety profiles. Specifically, inhibitors to tumor necrosis factor α (TNF- α) include etanercept, adalimumab, certolizumab, and infliximab. Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-23 (ustekinumab), IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab), and the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab). Biologics that inhibit TNF- α , p40IL-12/23, and IL-17 are also approved for the treatment of psoriatic arthritis. Oral treatments include traditional agents such as methotrexate, acitretin, cyclosporine, and the advanced small molecule apremilast, which is a phosphodiesterase 4 inhibitor. The most commonly prescribed light therapy used to treat plaque psoriasis is narrowband UV-B phototherapy.

Conclusions and Relevance Psoriasis is an inflammatory skin disease that is associated with multiple comorbidities and substantially diminishes patients' quality of life. Topical therapies remain the cornerstone for treating mild psoriasis. Therapeutic advancements for moderate to severe plaque psoriasis include biologics that inhibit TNF- α , p40IL-12/23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.



Full Text

Access through your institution

Read More About

Dermatology

Rheumatology

Psoriasis



Others Also Liked

JAMA®

JAMA Network®

Help



Get the latest from JAMA



Email address

Sign Up

[Privacy Policy](#) | [Terms of Use](#)

© 2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.

[Terms of](#)

[Use](#) | [Privacy Policy](#) | [Accessibility Statement](#) | [Cookie Settings](#)

POWERED BY  SILVERCHAIR

INFORMATION / SYSTEMS